Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

April 2023; 9 (2) Clinical/Scientific NoteOpen Access

Transcriptome and Genome Analysis Uncovers a DMD Structural Variant

A Case Report

View ORCID ProfileChiara Folland, Vijay Ganesh, View ORCID ProfileBen Weisburd, View ORCID ProfileCatriona McLean, Andrew J. Kornberg, View ORCID ProfileAnne O'Donnell-Luria, Heidi L. Rehm, View ORCID ProfileIgor Stevanovski, View ORCID ProfileSanjog R. Chintalaphani, Paul Kennedy, View ORCID ProfileIra W. Deveson, View ORCID ProfileGianina Ravenscroft
First published March 14, 2023, DOI: https://doi.org/10.1212/NXG.0000000000200064
Chiara Folland
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chiara Folland
Vijay Ganesh
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Weisburd
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Weisburd
Catriona McLean
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catriona McLean
Andrew J. Kornberg
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne O'Donnell-Luria
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne O'Donnell-Luria
Heidi L. Rehm
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Igor Stevanovski
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Igor Stevanovski
Sanjog R. Chintalaphani
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sanjog R. Chintalaphani
Paul Kennedy
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira W. Deveson
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ira W. Deveson
Gianina Ravenscroft
From the Centre for Medical Research, University of Western Australia (C.F., G.R.), Harry Perkins Institute of Medical Research, Perth, Australia; Center for Mendelian Genomics (V.G., B.W., A.O.-L., H.L.R.), Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neurology (V.G.), Brigham and Women's Hospital; Division of Genetics and Genomics (V.G., A.O.-L.), Boston Children's Hospital, MA; Department of Anatomical Pathology (C.M., P.K.), Alfred Health; Department of Medicine (C.M., P.K.), Central Clinical School, Monash University, Melbourne; Murdoch Children's Research Institute (A.J.K.); Department of Neurology (A.J.K.), Royal Children's Hospital; Department of Paediatrics (A.J.K.), University of Melbourne, Victoria, Australia; Center for Genomic Medicine (A.O.-L., H.L.R.), Massachusetts General Hospital, Boston, MA; Genomics Pillar (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research, Sydney, Australia; Centre for Population Genomics (I.S., S.R.C., I.W.D.), Garvan Institute of Medical Research and Murdoch Children's Research Institute, Australia; School of Clinical Medicine (S.R.C., I.W.D.), Faculty of Medicine and Health, UNSW Sydney, Australia; and School of Biomedical Sciences (G.R.), University of Western Australia, Perth, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gianina Ravenscroft
Full PDF
Citation
Transcriptome and Genome Analysis Uncovers a DMD Structural Variant
A Case Report
Chiara Folland, Vijay Ganesh, Ben Weisburd, Catriona McLean, Andrew J. Kornberg, Anne O'Donnell-Luria, Heidi L. Rehm, Igor Stevanovski, Sanjog R. Chintalaphani, Paul Kennedy, Ira W. Deveson, Gianina Ravenscroft
Neurol Genet Apr 2023, 9 (2) e200064; DOI: 10.1212/NXG.0000000000200064

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective Duchenne muscular dystrophy (DMD) is caused by pathogenic variants in the dystrophin gene (DMD). Hypermethylated CGG expansions within DIP2B 5′ UTR are associated with an intellectual development disorder. Here, we demonstrate the diagnostic utility of genomic short-read sequencing (SRS) and transcriptome sequencing to identify a novel DMD structural variant (SV) and a DIP2B CGG expansion in a patient with DMD for whom conventional diagnostic testing failed to yield a genetic diagnosis.

Methods We performed genomic SRS, skeletal muscle transcriptome sequencing, and targeted programmable long-read sequencing (LRS).

Results The proband had a typical DMD clinical presentation, autism spectrum disorder (ASD), and dystrophinopathy on muscle biopsy. Transcriptome analysis identified 6 aberrantly expressed genes; DMD and DIP2B were the strongest underexpression and overexpression outliers, respectively. Genomic SRS identified a 216 kb paracentric inversion (NC_000023.11: g.33162217-33378800) overlapping 2 DMD promoters. ExpansionHunter indicated an expansion of 109 CGG repeats within the 5′ UTR of DIP2B. Targeted genomic LRS confirmed the SV and genotyped the DIP2B repeat expansion as 270 CGG repeats.

Discussion Here, transcriptome data heavily guided genomic analysis to resolve a complex DMD inversion and a DIP2B repeat expansion. Longitudinal follow-up will be important for clarifying the clinical significance of the DIP2B genotype.

Duchenne muscular dystrophy (DMD) is a rare X-linked recessive muscular dystrophy caused by pathogenic loss-of-function variants in DMD (MIM: 300377). Some patients with DMD also demonstrate cognitive impairment.1 FRA12A is a distinct intellectual developmental disorder caused by a heterozygous expanded CGG repeat in the 5′ UTR of the disco-interacting protein 2 homolog B gene (DIP2B; MIM: 611379) on chromosome 12q13.

Here, we report a patient with DMD and mild intellectual disability harboring a novel DMD structural variant (SV) and a DIP2B short tandem repeat (STR) expansion. We exemplify how a combination of sequencing approaches, including transcriptome sequencing, genomic short-read sequencing (SRS), and targeted long-read sequencing (LRS), can be leveraged to resolve complex genetic variants.

Methods

Genomic SRS

Proband DNA was run on version 3 of a custom-designed muscle disease–targeted gene panel at Diagnostic Genomics, PathWest, as described previously.2

Illumina genome-wide SRS was performed at the Broad Institute Center for Mendelian Genomics (CMG), as described previously.3 SV and SNV analysis was performed using seqr (seqr.broadinstitute.org), which leverages Manta (Illumina).4 Genotyping of the DIP2B STR locus expansion was performed using ExpansionHunter.5

Genomic LRS and Methylation Profiling

LRS was performed at the Garvan Institute using Oxford Nanopore Technologies (ONT) “ReadUntil” selective sequencing to target the loci of interest (DMD and DIP2B), as demonstrated recently.6

Transcriptome Sequencing

Skeletal muscle transcriptome sequencing was performed at the CMG, as previously described.7 Aberrant expression events were detected using OUTRIDER.8 Skeletal muscle transcriptome sequencing samples from the CMG Rare Disease Cohort were used as controls (n = 172).

Highly expressed junctions from all 803 GTEx v3 muscle samples were used as controls for generating the Sashimi plot. The junction-spanning read counts were normalized to represent the average spanning read count per sample.

Results

The proband had a typical DMD clinical presentation with delayed motor development; he first walked at 18–20 months of age. He could walk fast but never ran and required carrying because of fatigue. He had frequent falls and used a Gowers' maneuver to raise from the floor. He had ASD with poor socialization at school, no friends, and engaged in solo play. His IQ and language were within normal limits. Fragile X and microarray testing were normal. There was no relevant family history.

Skeletal muscle immunoperoxidase staining revealed a complete absence of dystrophin (Figure 1, A and B), consistent with dystrophinopathy. Hematoxylin and eosin staining showed variation in myofiber size and some active degeneration (Figure 1C). No SNVs, indels, or SVs in DMD were detected by the initial analysis of genomic SRS data.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Patient Skeletal Muscle Histopathologic Images

Immunoperoxidase staining reveals the absence of DYS1 (DYS2 and DYS3 protein not shown) in the patient biopsy section (A), relative to an unaffected control (B). (C) Hematoxylin and eosin shows increased variation in myofiber size (10–90 µm) and some active degeneration. All images are at 100× magnification.

OUTRIDER analysis of muscle transcriptome data identified 6 aberrantly expressed genes, including DMD (Z score = −7.43, adjusted p value = 1.66 × 10−5; Figure 2A). Sashimi plots showed retained junctions in the 3′ region for the Dp71 and Dp40 isoforms and some 5′ exon 1 and intron 1 reads (Figure 2B). Manual investigation of genomic SRS data in the 5′ DMD preserved region revealed split reads in a pattern suggestive of a 216 kb paracentric inversion (NC_000023.11:g.33162217-33378800; eFigure 1, links.lww.com/NXG/A587). Analysis of the breakpoint junction reads identified microhomology domains within 2 transposons, a telomeric SINE, and a centromeric DNA/hAT-Charlie element, suggestive of a mechanism of microhomology-mediated break-induced repair. The inversion overlaps promoters for the (cortical) DMD isoform (Dp427c) and the full-length muscle isoform (Dp427m). No common inversions are seen in the DMD locus in gnomAD-SV (v2.1).

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Skeletal Muscle Transcriptome Analysis

(A) Volcano plot from OUTRIDER analysis showing aberrant gene expression detected in a patient. (B) Sashimi plots of the patient (top) and normalized splice junctions from 803 muscle control samples from GTEx v3 (bottom). The major skeletal muscle DMD isoforms were obtained from Refseq.

DIP2B overexpression was the strongest outlier (Z score = 6.14, adjusted p value = 5.00 × 10−7: Figure 2A). Manual inspection of the DIP2B locus in genomic SRS data revealed a drop in coverage within the 5′ UTR (eFigure 1, links.lww.com/NXG/A587). STR genotyping indicated a repeat genotype of 109 (80-186)/7 (7-7). This was the largest expansion in DIP2B in all samples within the CMG and RGP Rare Disease Cohorts (n = 3,245). Only 3 samples in gnomAD (n = 18,511) had genotypes in this range.

Targeted LRS6 confirmed the presence of the large inversion spanning the promoters of Dp427c and Dp427m and the repeat expansion in DIP2B (Figures 3A, 3B). The expanded DIP2B allele was estimated at 270 × CGG repeats. There was no evidence of hypermethylation on the expanded haplotype, which was predominantly unmethylated at the DIP2B promoter in whole blood (Figure 3C). The methylation status of DIP2B was not evaluated in other tissues such as brain.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3 Targeted Long-Read Sequencing Analysis of the DMD and DIP2B Loci

(A) Alignments showing a large inversion in DMD spanning the promoters of Dp427c and Dp427m (reverse strand gene). The left- and right-side breakpoints are shown magnified in the black boxes. (B) Genotyping (left) and methylation profiling (right) of the DIP2B 5′ UTR STR expansion locus. A heterozygous expansion (270 × CGG) was detected in the patient but absent in healthy controls (n = 10). There was no evidence of DNA hypermethylation in the patient profile, compared with controls. b.p., base pairs; hap, haplotype; UTR, untranslated region.

Discussion

Here, we describe the utility of transcriptome combined with genomic SRS and LRS to identify a complex DMD inversion.

Transcriptome sequencing is becoming increasingly important for molecular diagnosis of patients with Duchenne and Becker muscular dystrophy who have dystrophinopathy based on muscle biopsy but negative on genomic testing.3,9 SVs are increasingly recognized in DMD and can be overlooked without transcriptome data,3 contributing to the 1.5%–7% of DMD variants that are not detectable through genomic analysis.9 Intronic variants leading to pseudoexon inclusion also evade conventional DNA testing.9

Genomic LRS offers the capacity to detect pathogenic substitutions, copy number changes, complex rearrangements, repeat expansions, and methylation differences, all within a single data source. These complex variants are challenging to identify through clinical genetic testing, which typically rely on SRS, such as exome sequencing or gene panels. The versatility of LRS has made it an active area of investigation in muscular dystrophy; recent studies have leveraged LRS to identify complex variants in patients with DMD previously lacking a genetic diagnosis, including intronic repeat expansions,10 large inversions,11 and deep intronic splice-altering SNVs.11 In addition, LRS can be used to study transcriptome dynamics involved in the pathology of muscular dystrophy12; LRS is well adapted to analyze repetitive elements, can clearly detect exon connectivity, and shows whole isoforms with high confidence.12

The clinical significance of DIP2B overexpression in our patient with DMD remains unknown. DIP2B is associated with FRA12A, a folate-sensitive chromosomal fragile site associated with an autosomal dominant intellectual developmental disorder.13 The molecular basis of FRA12A is an expansion of the CGG repeat locus located in the CpG island at the 5′ UTR of DIP2B.13. Methylation of the expanded allele and a ∼50% reduction in DIP2B expression were previously identified in all patients with DIP2B-related intellectual disability.13 The estimated sizes of the previously described expansions were 273–306 × CGG.13 An unaffected carrier of a smaller and unmethylated expansion showed increased levels of DIP2B mRNA; thus, repeat elongation may behave as a transcriptional enhancer.13 These prior findings suggest that the unmethylated 270 × CGG expansion and DIP2B transcript overexpression do not contribute to our patient's clinical phenotype, although we note that this was not assessed in brain tissue.

DMD can be associated with cognitive involvement, including autism spectrum disorders.14 It is difficult to discern whether the cognitive phenotype in our single patient is due to the disruption to the Dp427c isoform (which has previously been shown to cause CNS comorbidities1) or the DIP2B overexpression. It is also possible that both genotypes and other genetic variants create a blended cognitive phenotype. There are no available data on the impact of DIP2B overexpression. FMR1 premutation carriers who have excessive FMR1 transcript levels develop fragile X–associated tremor/ataxia syndrome.15 An analogous phenomenon could apply to DIP2B. Furthermore, the techniques used previously to size DIP2B repeats (PCR and Southern blotting)13 are imprecise; therefore, an accurate pathogenic repeat threshold for DIP2B expansions remains undetermined, adding to the difficulty of interpreting the clinical significance of this variant in our patient. Longitudinal follow-up will be important to determine whether the patient may have mild symptoms of this repeat or may develop a later-onset neurodegenerative phenotype. Additional cases are needed to discern whether there is a phenotype associated with DIP2B overexpression. Further long-read studies are required to explore the pathogenic range of DIP2B expansions.

Study Funding

This project was supported by an Australian NHMRC Ideas Grant (APP2002640) and NHMRC Investigator Fellowship (APP2007769) to G.R. Short-read sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute (NHGRI), the National Eye Institute, and the National Heart, Lung, and Blood Institute grant UM1HG008900 and NHGRI U01HG011755.

Disclosure

The authors have no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Appendix Authors

Table

Footnotes

  • The Article Processing Charge was funded by the authors.

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

  • Submitted and externally peer reviewed. The handling editor was Associate Editor Margherita Milone, MD, PhD.

  • Received September 20, 2022.
  • Accepted in final form January 27, 2023.
  • Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Ricotti V,
    2. Mandy WPL,
    3. Scoto M, et al.
    Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016;58(1):77-84. doi:10.1111/dmcn.12922
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ravenscroft G,
    2. Clayton JS,
    3. Faiz F, et al.
    Neurogenetic fetal akinesia and arthrogryposis: genetics, expanding genotype-phenotypes and functional genomics. J Med Genet. 2021;58(9):609-618. doi:10.1136/jmedgenet-2020-106901
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Waddell LB,
    2. Bryen SJ,
    3. Cummings BB, et al.
    WGS and RNA studies diagnose noncoding DMD variants in males with high creatine kinase. Neurol Genet. 2021;7(1):e554. doi:10.1212/NXG.0000000000000554
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Chen X,
    2. Schulz-Trieglaff O,
    3. Shaw R, et al.
    Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220-1222. doi:10.1093/bioinformatics/btv710
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Dolzhenko E,
    2. Deshpande V,
    3. Schlesinger F, et al.
    ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. Bioinformatics. 2019;35(22):4754-4756. doi:10.1093/bioinformatics/btz431
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Stevanovski I,
    2. Chintalaphani SR,
    3. Gamaarachchi H, et al.
    Comprehensive genetic diagnosis of tandem repeat expansion disorders with programmable targeted nanopore sequencing. Sci Adv. 2022;8(9):eabm5386. doi:10.1126/sciadv.abm5386
    OpenUrlCrossRef
  7. 7.↵
    1. Cummings BB,
    2. Marshall JL,
    3. Tukiainen T, et al.
    Improving genetic diagnosis in mendelian disease with transcriptome sequencing. Sci Transl Med. 2017;9(386):eaal5209. doi:10.1126/scitranslmed.aal5209
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Brechtmann F,
    2. Mertes C,
    3. Matusevičiūtė A, et al.
    OUTRIDER: a statistical method for detecting aberrantly expressed genes in RNA sequencing data. Am J Hum Genet. 2018;103(6):907–917. doi:10.1016/j.ajhg.2018.10.025
    OpenUrlCrossRef
  9. 9.↵
    1. Waldrop MA,
    2. Moore SA,
    3. Mathews KD, et al.
    Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy. Hum Mutat. 2022;43(4):511–528. doi:10.1002/humu.24343
    OpenUrlCrossRef
  10. 10.↵
    1. Miller DE,
    2. Sulovari A,
    3. Wang T, et al.
    Targeted long-read sequencing identifies missing disease-causing variation. Am J Hum Genet. 2021;108(8):1436–1449. doi:10.1016/j.ajhg.2021.06.006
    OpenUrlCrossRef
  11. 11.↵
    1. Bruels CC,
    2. Littel HR,
    3. Daugherty AL, et al.
    Diagnostic capabilities of nanopore long-read sequencing in muscular dystrophy. Ann Clin Transl Neurol. 2022;9(8):1302–1309. doi:10.1002/acn3.51612
    OpenUrlCrossRef
  12. 12.↵
    1. Mitsuhashi S,
    2. Nakagawa S,
    3. Sasaki-Honda M,
    4. Sakurai H,
    5. Frith MC,
    6. Mitsuhashi H
    . Nanopore direct RNA sequencing detects DUX4-activated repeats and isoforms in human muscle cells. Hum Mol Genet. 2021;30(7):552–563. doi:10.1093/hmg/ddab063
    OpenUrlCrossRef
  13. 13.↵
    1. Winnepenninckx B,
    2. Debacker K,
    3. Ramsay J, et al.
    CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. Am J Hum Genet. 2007;80(2):221–231. doi:10.1086/510800
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Simone M,
    2. Margari L,
    3. Pompamea F, et al.
    Autism spectrum disorder and Duchenne muscular dystrophy: a clinical case on the potential role of the dystrophin in autism neurobiology. J Clin Med. 2021;10(19):4370. doi:10.3390/jcm10194370
    OpenUrlCrossRef
  15. 15.↵
    1. Cabal-Herrera AM,
    2. Tassanakijpanich N,
    3. Salcedo-Arellano MJ,
    4. Hagerman RJ
    . Fragile X-associated tremor/ataxia syndrome (FXTAS): pathophysiology and clinical implications. Int J Mol Sci. 2020;21(12):E4391. doi:10.3390/ijms21124391
    OpenUrlCrossRef

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Trinucleotide repeat diseases
  • Muscle disease

Alert Me

  • Alert me when eletters are published
Neurology Genetics: 9 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise